Relapsed, Refractory Multiple Myeloma Progression Free Survival Prolonged with Drug Combo
Elotuzumab in combination with bortezomib and dexamethasone prolongs…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreElotuzumab in combination with bortezomib and dexamethasone prolongs…
The Multiple Myeloma Research Foundation (MMRF) and the…
In a video posted on Healio’s Hematology-Oncology…
A three-drug combination that includes thalidomide, in place of cyclophosphamide,…
The U.S. Food and Drug Administration has designated Darzalex…
A randomized Phase 3 clincal trial has concluded that…